What Pearsanta does

Pearsanta, Inc. is a Richmond, Virginia-based medical diagnostics company operating as a wholly-owned subsidiary of Aditxt, a publicly-traded biotechnology company. Founded in 2023 and incorporated in Delaware, Pearsanta delivers personalized diagnostic and monitoring solutions under its "Health by the Numbers" positioning, targeting both healthcare providers and individual patients. The company operates a CLIA-certified, CAP-accredited monitoring center that handles biosample collection, processing, and delivery of actionable health information, providing a regulated infrastructure footprint for commercial laboratory-developed testing.

The company's core asset is the Mitomic™ testing platform, acquired from MDNA Life Sciences on January 8, 2024. Mitomic™ uses patented mitochondrial DNA (mtDNA)-based methodology for early disease and cancer detection, with current diagnostic tests covering endometriosis and prostate cancer. The technology is described as patent-protected, and the company emphasizes specificity advantages and multidimensional personalization relative to conventional one-size-fits-all diagnostics. No AI/ML capability is referenced; the differentiator is biomarker chemistry and assay architecture rather than algorithmic interpretation.

Pearsanta runs a sales-led, hybrid go-to-market: B2B sales through healthcare provider networks (hospitals, clinics, medical practices) and B2C direct-to-patient testing. Revenue is generated through diagnostic testing services, with the revenue stream described as subscription/recurring in source material. Pricing is not publicly disclosed. Marketing presence is anchored on the corporate website (pearsanta.com) with phone and email as bottom-of-funnel contact channels. The company has no disclosed standalone funding rounds, no public customer logos, and no named management team; commercial scale signals (revenue, test volume, headcount over time) are not provided.

Name

Pearsanta

Legal name

Pearsanta, Inc.

Website

https://pearsanta.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Pearsanta is a Richmond, Virginia-based medical diagnostics subsidiary of Aditxt that delivers personalized diagnostic testing using its proprietary Mitomic™ mitochondrial DNA platform for early disease and cancer detection, targeting healthcare providers and patients.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Molecular diagnostics
• Mitochondrial DNA testing
• Cancer screening
• Early disease detection
• Diagnostic laboratory services

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Testing Services: Pearsanta generates revenue through providing diagnostic testing services focused on early disease and cancer detection using their proprietary mitochondrial DNA technology platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Pearsanta delivers personalized, data-driven diagnostic and monitoring solutions through its proprietary Mitomic™ testing platform, which uses mitochondrial DNA (mtDNA) for early disease and cancer detection. The portfolio includes specific diagnostic tests for endometriosis and prostate cancer, supported by a CLIA-certified, CAP-accredited monitoring center that handles biosample collection, processing, and delivery of actionable health information to healthcare providers and patients.

Product overview

Pearsanta™ operates as a medical diagnostic and innovation company delivering personalized, data-driven diagnostic and monitoring solutions through its 'Health by the Numbers' approach. The company's product portfolio centers on the acquired Mitomic™ testing platform, which provides early disease and cancer detection using mitochondrial DNA. This core technology platform is complemented by specific diagnostic tests for endometriosis and prostate cancer. The company leverages its CLIA-certified, CAP-accredited monitoring center to handle biosample collection, processing, and delivery of actionable health information, with the goal of enabling providers and patients to detect and monitor health conditions through precise, personalized diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

• Mitomic™ Testing Platform A proprietary diagnostic testing platform specializing in early disease and cancer detection using mitochondrial DNA, providing the core technology backbone for Pearsanta's personalized diagnostic and monitoring solutions for healthcare providers and patients.
• Endometriosis Diagnostic Test A diagnostic test for endometriosis included as part of the Mitomic™ testing platform, designed for early detection of the condition in patients using mitochondrial DNA markers.
• Prostate Cancer Diagnostic Test A diagnostic test for prostate cancer included as part of the Mitomic™ testing platform, utilizing mitochondrial DNA for early cancer detection in patients.
• CLIA-certified, CAP-accredited Monitoring Center Pearsanta's operational infrastructure featuring a CLIA-certified and CAP-accredited monitoring center for processing diagnostic tests and delivering actionable health information to providers and patients.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• MDNA Life SciencescoreTechnology or Integration · 8 January 2024Pearsanta acquired MDNA Life Sciences' proprietary Mitomic™ testing platform in January 2024. This acquisition provides Pearsanta with mitochondrial DNA-based diagnostic technology for early disease and cancer detection, including tests for endometriosis and prostate cancer.

Recent moves4 records

Expansion highlights2 records

Direct peers

• MDNA Life Sciences: The originator of the Mitomic™ mitochondrial DNA testing platform that Pearsanta acquired in January 2024. Most directly comparable as a peer in mtDNA-based diagnostics for cancer and other diseases.
• Natera: Molecular diagnostics company with established women's health (including endometriosis-related work) and oncology tests. Competes for the same provider channel and similar clinical use cases as Pearsanta.
• Guardant Health: Liquid biopsy and molecular diagnostics leader focused on oncology. Competes directly in the early cancer detection space Pearsanta addresses with its Mitomic™ prostate cancer test.
• Personalis: Molecular diagnostics company focused on minimal residual disease and cancer detection. Directly comparable as a smaller, molecular-diagnostics-only commercial-stage peer.

Broad incumbents

• Exact Sciences: Established cancer screening and diagnostics company with Cologuard and Oncotype products. Operates in the same early-detection, oncology diagnostic market Pearsanta targets.
• Myriad Genetics: Diversified molecular diagnostics company with established women's health and oncology franchises. Competes broadly in personalized genetic/molecular testing for cancer risk and prognosis.
• NeoGenomics: Oncology-focused clinical laboratory and molecular diagnostics provider serving hospitals and oncologists. Directly comparable B2B oncology channel and CLIA/CAP lab operations.
• Tempus AI: AI-enabled precision medicine and molecular profiling company focused on oncology. Competes in data-driven, personalized diagnostics for oncology providers and patients.
• Bio-Techne: Life science tools and diagnostics company whose diagnostics segment competes in molecular and protein-based specialty diagnostics. Adjacent peer given Pearsanta's molecular testing focus.

Emerging players

• Mainz Biomed: Earlier-stage molecular diagnostics company developing molecular cancer screening tests. Comparable to Pearsanta in size, stage, and focus on early cancer detection via proprietary molecular assays.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/pearsanta_inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pearsanta